Author: PWeekly
Anti-Science Words Don’t Hurt Science: They Just Hurt Us
Dec 22, 2022
As a child, I was taught that “sticks and stones could break my bones, but words could never harm...
Read MoreRetinal Age: A Novel Biomarker for Incident ESKD
Dec 22, 2022
Prior research suggests that biological age, a measure of the body’s functional capability, is an...
Read MoreFor Acute Musculoskeletal Injury, MOVE, Not RICE
Dec 20, 2022
Approximately 30% of all visits to a primary care physician are for musculoskeletal issues, yet...
Read MorePrior Authorization Negative Impacts: By the Numbers
Dec 20, 2022
While many medical professionals like to give voice to their frustrations regarding prior...
Read MorePreventing & Treating Chronic Pain in Breast Cancer Survivors: Exploring Clinician Perceptions
Dec 20, 2022
Physical and psychosocial symptoms, such as pain, are common after breast cancer treatment is...
Read MoreMetabolic Tumor Volume Predicts Response to Loncastuximab Tesirine in DLBCL
Dec 16, 2022
Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of...
Read MoreBlinatumomab Candidate for Standard-of-Care in Newly Diagnosed B-ALL
Dec 15, 2022
measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were...
Read MoreNovel Therapy May Replace Standard-of-Care Prophylaxis for GVHD
Dec 15, 2022
Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...
Read MoreOdronextamab Scores in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Dec 15, 2022
Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...
Read MoreHigh-Dose Chemotherapy Plus ASCT Superior to Standard Immune-Chemotherapy in Primary CNS Lymphoma
Dec 15, 2022
Consolidation high-dose chemotherapy followed by autologous stem cell transplantation (HCT/ASCT)...
Read MoreChemo-Endocrine Therapy Worse for Cognition than Endocrine Therapy Alone
Dec 12, 2022
Chemo-endocrine therapy has a greater negative effect on cancer-related cognitive impairment...
Read MoreNeoadjuvant Trastuzumab Deruxtecan Shows Clinical Activity in HER2-Low Breast Cancer
Dec 12, 2022
Patients with localized, hormone receptor-positive, HER2-low breast cancer treated in the...
Read MoreBenefit of Adjuvant Abemaciclib Continues to Deepen at Longer Follow-Up
Dec 12, 2022
With additional follow-up, the benefit of adjuvant abemaciclib for patients with...
Read MoreFirstline Ribociclib Plus Endocrine Therapy Shows Superior PFS for HR-Positive/HER2-Negative Advanced Breast Cancer
Dec 12, 2022
A first prospective, head-to-head study showed superior progression-free survival of ribociclib...
Read MoreRacial Disparity in the Breast Cancer Tumor Microenvironment
Dec 12, 2022
Residual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary...
Read MoreOpportunity Loves Uncertainty
Nov 28, 2022
Change is a single constant. Oftentimes, with change, there can be much uncertainty about...
Read MoreThankful for the Great Honor of Being a Doctor
Nov 22, 2022
Since the COVID-19 pandemic started, doctors have seen many bad things and experienced burnout...
Read MoreMIRROR RCT Trial: Addressing Gout Following Kidney Transplant
Nov 21, 2022
Results from the MIRROR RCT trial, presented at the 2022 American Society of Nephrology’s Kidney...
Read More